Cellectar Biosciences, Inc.

CLRB

US15117F8077

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.03 ^USD	+0.33%		0.00%	+9.39%

Mar. 28	Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	MT
Mar. 28	Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	MT

Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 27, 2024 at 06:31 am EDT

Cellectar Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 37.98 million compared to USD 28.6 million a year ago. Basic loss per share from continuing operations was USD 3.11 compared to USD 4.05 a year ago.

Latest news about Cellectar Biosciences, Inc.

Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	Mar. 28	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	Mar. 28	MT
Transcript : Cellectar Biosciences, Inc., 2023 Earnings Call, Mar 27, 2024	Mar. 27
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	Mar. 04	CI
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study	Jan. 30	CI
Sector Update: Health Care Stocks Advance Late Afternoon	Jan. 22	MT
Cellectar Biosciences Shares Rise as Drug Shows Promise on Complete Central Nervous System Clearance on Cancer Type	Jan. 22	MT
Cellectar Biosciences, Inc. Reports Complete Central Nervous System Clearance in Relapsed/Refractory Waldenstrom?s Macroglobulinemia Patient	Jan. 22	CI
Transcript : Cellectar Biosciences, Inc. - Special Call	Jan. 19
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data	Jan. 16	CI
Cellectar Biosciences Partners with MiBA to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting	Jan. 11	CI
Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating	Jan. 09	MT
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	Jan. 08
Investors lower their expectations	Jan. 08
Transcript : Cellectar Biosciences, Inc. - Special Call	Jan. 08
Cellectar's blood cancer therapy succeeds in late-stage study	Jan. 08	RE
Cellectar's blood cancer therapy succeeds in trial	Jan. 08	RE
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia	Jan. 08	CI
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation	Dec. 19	CI
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Transcript : Cellectar Biosciences, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Cellectar Biosciences, Inc. to Release Top-Line Data from Wm Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024	Nov. 02	CI
Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.	Nov. 01	CI
Cellectar Biosciences, Florida Cancer Specialists & Research Institute to Collaborate on Lymphoma Research	23-10-25	MT

Chart Cellectar Biosciences, Inc.

Duration

Period

More charts

Company Profile

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstromâs macroglobulinemia (WM).

Sector

Pharmaceuticals

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.03 USD

Average target price

15 USD

Spread / Average Target

+395.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CELLECTAR BIOSCIENCES, INC.	+9.39%	97.75M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals